Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Concurrent with IPO, ChemoCentryx privately raises $12mm from GSK and Techne

Executive Summary

At the same time it closed its $41.8mm IPO, ChemoCentryx Inc. (treatments for autoimmune disease, inflammation, and cancer that target the chemokine system) raised $12mm by selling common stock to GlaxoSmithKline PLC and Techne Corp., both existing shareholders, in concurrent private placements. GSK (which had initially acquired a $25mm equity stake in 2006 when the companies partnered on inflammation targets) bought 700k shares while Techne (which first acquired stock in a 1997 agreement) purchased 500k shares, all at the $10 IPO price. GSK and Techne now own 21.7% and 18.3% stakes, respectively, in ChemoCentryx.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Private Investment in Public Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register